Abiomed, Inc. (0H7S.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 03:24PM GMT
| Previous close | 380.73 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 16.932B |
| Beta (5Y monthly) | 1.31 |
| PE ratio (TTM) | 77.13 |
| EPS (TTM) | 4.94 |
| Earnings date | 01 Feb 2023 - 06 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
- Business Wire
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
DANVERS, Mass., December 21, 2022--Abiomed Announces First Patients Enrolled in FDA Pivotal Trial for Impella ECP, World’s Smallest Heart Pump
- Motley Fool
This Monster Dividend Stock Isn't Done Growing
Johnson & Johnson (NYSE: JNJ) is in the midst of a transition. One way the business can accelerate its plans for growth is via acquisitions, and Johnson & Johnson has been busy on that front of late. Horizon Therapeutics Public (NASDAQ: HZNP), a healthcare business that makes medicines to treat autoimmune and inflammatory diseases, issued a press release on Nov. 29 stating that it is in "preliminary discussions" regarding a potential acquisition of its business.
© 2023 Yahoo. All rights reserved.
